Cost-Effective Pharmacological Prevention of Acute Coronary Syndromes

Author： Monaco C.   Cianflone D.   Summaria F.   Maseri A.   Crea F.  

Publisher： Academic Press

ISSN： 1043-6618

Source： Pharmacological Research, Vol.37, Iss.6, 1998-06, pp. : 469-475

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GPIIb-IIIa antagonists cost effective in acute coronary syndromes

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of ticagrelor in acute coronary syndromes

By Henriksson Martin   Janzon Magnus  

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Iss. 1, 2013-02 ,pp. : 9-18

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Anticoagulation in Acute Coronary Syndromes

By Latour-Pérez Jaime   de-Miguel-Balsa Eva  

PharmacoEconomics, Vol. 30, Iss. 4, 2012-04 ,pp. : 303-321

Adis International

Access to resources Recommend Favorite

Eptifibatide cost effective for acute coronary disorders

By  

Inpharma, Vol. 1, Iss. 1326, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Patients' adherence to secondary prevention pharmacotherapy after acute coronary syndromes

By Kassab Yaman  

International Journal of Clinical Pharmacy, Vol. 35, Iss. 2, 2013-04 ,pp. : 275-280

Springer Publishing Company

Access to resources Recommend Favorite